This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Various				
Coronary artery disease (CAD); Parkinson's disease (PD)	Myeloperoxidase (MPO)	<i>In vitro</i> and rat studies suggest a series of MPO inhibitors could help treat inflammation-associated diseases such as CAD and PD. SAR studies and <i>in vitro</i> testing of alkylindoles identified compounds that selectively inhibit MPO with low nanomolar IC ₅₀ values. In a low-density lipoprotein (LDL) oxidation assay, two of the compounds inhibited MPO-mediated LDL oxidation with low nanomolar IC ₅₀ values. Select compounds showed a good safety profile in normal rats. Next steps could include testing the compounds in animal models for CAD. AZD3241, an MPO inhibitor from AstraZeneca plc, is in Phase II testing to treat PD.	Patent and licensing status unavailable	Soubhye, J. <i>et al. J. Med. Chem.</i> ; published online April 14, 2013; doi:10.1021/jm4001538 Contact: Pierre G. Van Antwerpen, Free University of Brussels, Brussels, Belgium e-mail: pvantwer@ulb.ac.be
SciBX 6(17); doi:10.1038/scibx.2013.420 Published online May 2, 2013				